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Abstract
Pathological expansion of a G4C2 repeat, located in the 5' regulatory region of
C9orf72, is the most common genetic cause of frontotemporal lobar degeneration
(FTLD) and amyotrophic lateral sclerosis (ALS). C9orf72 patients have highly
variable onset ages suggesting the presence of modifying factors and/or
anticipation. We studied 72 Belgian index patients with FTLD, FTLD–ALS or ALS
and 61 relatives with a C9orf72 repeat expansion. We assessed the effect of
G4C2 expansion size on onset age, the role of anticipation and the effect of repeat
size on methylation and C9orf72 promoter activity. G4C2 expansion sizes varied
in blood between 45 and over 2100 repeat units with short expansions (45–78
units) present in 5.6% of 72 index patients with an expansion. Short expansions
co-segregated with disease in two families. The subject with a short expansion
in blood but an indication of mosaicism in brain showed the same pathology as
those with a long expansion. Further, we provided eviden...
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I Gijselinck1,2, S Van Mossevelde1,2, J van der Zee1,2, A Sieben1,2,3, S Engelborghs2,4, J De Bleecker3, A Ivanoiu5, O Deryck6, D Edbauer7,8,
M Zhang9, B Heeman1,2, V Bäumer1,2, M Van den Broeck1,2, M Mattheijssens1,2, K Peeters1,2, E Rogaeva9,10, P De Jonghe1,2,11, P Cras2,11,
J-J Martin2, PP de Deyn2,4,12, M Cruts1,2 and C Van Broeckhoven1,2 on behalf of the BELNEU CONSORTIUM13
Pathological expansion of a G4C2 repeat, located in the 5' regulatory region of C9orf72, is the most common genetic cause of
frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). C9orf72 patients have highly variable onset ages
suggesting the presence of modifying factors and/or anticipation. We studied 72 Belgian index patients with FTLD, FTLD–ALS or
ALS and 61 relatives with a C9orf72 repeat expansion. We assessed the effect of G4C2 expansion size on onset age, the role of
anticipation and the effect of repeat size on methylation and C9orf72 promoter activity. G4C2 expansion sizes varied in blood
between 45 and over 2100 repeat units with short expansions (45–78 units) present in 5.6% of 72 index patients with an expansion.
Short expansions co-segregated with disease in two families. The subject with a short expansion in blood but an indication of
mosaicism in brain showed the same pathology as those with a long expansion. Further, we provided evidence for an association of
G4C2 expansion size with onset age (Po0.05) most likely explained by an association of methylation state of the 5' ﬂanking CpG
island and expansion size in blood (Po0.0001) and brain (Po0.05). In several informative C9orf72 parent–child transmissions, we
identiﬁed earlier onset ages, increasing expansion sizes and/or increasing methylation states (P= 0.0034) of the 5' CpG island,
reminiscent of disease anticipation. Also, intermediate repeats (7–24 units) showed a slightly higher methylation degree
(Po0.0001) and a decrease of C9orf72 promoter activity (Po0.0001) compared with normal short repeats (2–6 units). Decrease of
transcriptional activity was even more prominent in the presence of small deletions ﬂanking G4C2 (Po0.0001). Here we showed
that increased methylation of CpGs in the C9orf72 promoter may explain how an increasing G4C2 size lead to loss-of-function
without excluding repeat length-dependent toxic gain-of-function. These data provide insights into disease mechanisms and have
important implications for diagnostic counseling and potential therapeutic approaches.
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INTRODUCTION
A pathological expansion of a hexanucleotide repeat, G4C2,
located in the 5' regulatory region of C9orf72 is the most frequent
hereditary cause of frontotemporal lobar degeneration (FTLD) and
amyotrophic lateral sclerosis (ALS).1–3 Moreover, it is the most
frequent causal mutation in patients suffering from both FTLD and
ALS and in families segregating both clinical phenotypes
(FTLD–ALS). Together with the clinical and pathological overlap
between these two disorders, identiﬁcation of C9orf72 provided
strong evidence for the presence of an FTLD–ALS disease
continuum of which the pure clinical forms of FTLD and ALS
represent the two extremes.
C9orf72 is transcribed in three major transcripts encoding two
protein isoforms (C9orf72 a and b), which may have a role in
autophagy and endosomal trafﬁcking4 and might be involved in
regulating endoplasmatic reticulum stress.5 The repeat sequence
is part of the functional core promoter of all three C9orf72
transcripts2 (Supplementary Figure S1).
In FTLD and ALS patients carrying a G4C2 expansion, allele-
speciﬁc reduction of C9orf72 expression in brain tissue1,2,6–9 and
hypermethylation of the G4C2 repeat
10 and the ﬂanking CpG
island11–15 was observed. Hypermethylation of CpG-rich promo-
ters has been associated with transcriptional silencing in noncod-
ing repeat expansion disorders like, for example, Fragile X
syndrome,16,17 and CpG methylation state has been directly
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correlated with repeat expansion size in Friedreich ataxia.18
Further, both sense and antisense transcription and repeat-
associated non-ATG translation of the expanded repeat result in
nuclear RNA foci and aggregated dipeptide repeat (DPR)
neuropathology.1,19–24 However, the exact role of each mechan-
ism in the disease remains unclear. Some observations might
represent benign side effects and conversely, the proposed
mechanisms might have an effect on speciﬁc transcripts leading
to degeneration of particular neuronal populations affected in
FTLD or ALS.
The pathogenic nature of the repeat depends on its size but the
cut-off between normal and pathogenic alleles is not well
established. In control populations, the normal repeat sizes
ranged between 2 and 24 units with those of 7–24 units
potentially acting as risk alleles for disease and hence named
intermediate alleles.25 Some studies consider repeats of430 units
as pathogenic,3 whereas others use a cut-off of 60 units,2
depending on the upper limit of the repeat-primed PCR detection
method. Exact sizing of the expanded G4C2 repeat has been
limited because of its 100% GC content, its large size, somatic
instability and the repetitive nature of its ﬂanking sequences.
Southern blot hybridization studies visualized the expanded
alleles and estimated that the size of most repeat expansions
ranged between several hundred and several thousand repeat
units.1,6,26–32 G4C2 hexanucleotide repeat sizes of 25–60 repeat
units were rarely observed in FTLD, ALS and related
disorders;6,26,27,30,33–38 however, in most of the studies
co-segregation with disease or other arguments for pathogenicity
were not observed in families. The apparent size gap between
normal and expanded repeat alleles suggests that these repeat
sizes might have the propensity to either rapidly expand to
pathological sizes or contract to normal sizes. Therefore, the
shortest size of a pathological G4C2 repeat expansion outside the
pathogenic size range remains elusive.
In most repeat expansion disorders, the size of a pathological
repeat expansion inﬂuences the severity of the clinical symptoms.
For example, in myotonic dystrophy type I caused by an expanded
(CTG)n repeat located in the noncoding region of DMPK,
39 longer
expansions correlate with more severe symptoms and an earlier
onset age in successive generations because of genetic anticipa-
tion. Also, in Friedreich ataxia, the onset age is inﬂuenced by the
size of a (GAA)n repeat expansion within the ﬁrst intron of FXN.
40
In this context, we observed in 26 G4C2 expansion carriers a highly
variable onset age from 42 to 69 years and a disease duration of
1.5 to 17 years, as well as carriers living up to 76 years without
signs of disease, suggesting the presence of disease-modifying
factors.2,41 A disease liability risk curve calculated that by the age
of 70 years, 91% of the carriers will be affected.41 Further, along
with others, we described in FTLD–ALS families segregating a
C9orf72 G4C2 repeat expansion a decreasing onset age of 7 to 11
years in each younger generation2,41–46 suggesting disease
anticipation. Whether the clinical variability of FTLD–ALS is due
to size variability of the C9orf72 G4C2 expansion is still unclear.
Studies examining the effect of repeat length on onset age could
not establish an inverse correlation.6,26,30–32 Studies of genetic
anticipation in C9orf72 families are lacking.
In this study, we aimed to address these unresolved concerns
by evaluating the correlation of the size of the G4C2 repeat and
onset age of FTLD–ALS in families and sporadic repeat expansion
carriers. In addition, we examined the effect of repeat size
variability on CpG methylation of the C9orf72 repeat region and
on C9orf72 transcriptional activity, including the effect of the
presence of disease-related small insertion/deletion (indels)
polymorphisms in the 3' ﬂanking sequences.25
MATERIALS AND METHODS
Participants and study design
The Belgian FTLD and ALS cohorts used in this study consisted of 549
index patients with FTLD of which 35 with concomitant FTLD and ALS
(FTLD–ALS), and 210 patients with ALS. Of 72 index patients, blood-derived
DNA was used in this study and in addition 61 affected or at-risk relatives
with a repeat expansion were collected. Patients were ascertained in
Belgium through an ongoing multicenter collaboration of neurology
departments and memory clinics partnering in the Belgian Neurology
(BELNEU) consortium of neurologists afﬁliated to specialized memory
clinics, neuromuscular reference centers and neurology departments in
Belgium.2,41 Additional patients were included who had initially been
referred to the Diagnostic Service Facility for medical genetic testing. All
frontotemporal dementia (FTD) patients were evaluated using a standard
diagnostic protocol including detailed recording of clinical and family
history, neuropsychological testing, neurological examination, biochemical
analyses, and neuroimaging (structural (brain computed tomography or
magnetic resonance imaging) and in a selection of patients functional
(single photon emission computed tomography or ﬂuorodeoxyglucose-
positron emission tomography)) and were followed longitudinally on a
regular basis. Clinical diagnoses of behavioral variant FTD, progressive
non-ﬂuent aphasia or semantic dementia were based on established
clinical criteria for FTLD47,48 and was made by consensus by at least two
neurologists. ALS patients had a clinical diagnosis of deﬁnite, probable or
possible ALS according to the revisited El Escorial criteria for ALS.49,50 The
Belgian control cohort consisted of 1044 unrelated individuals free of
personal and familial history of neurodegenerative or psychiatric diseases
and with a mini-mental state examination score424. All participants and/
or their legal guardian provided written informed consent for participation
in clinical and genetic studies. The clinical study protocol and the informed
consent forms used in patient ascertainment were approved by the ethics
committee of the respective hospitals. The genetic study protocols and
informed consent forms were approved by the ethics committees of the
University of Antwerp and the University Hospital Antwerp, Belgium.
Procedures
Blood DNA of all 133 G4C2 expansion carriers and DNA from frontal cortex,
temporal cortex and cerebellum of four patients with a long expansion
(480 units) and one with a short expansion (o80 units) was analyzed
with a 'short expansion PCR'. We used the KAPA2G Robust HotStart DNA
polymerase (Kapa Biosystems, Wilmington, MA, USA) with a primer pair
ﬂanking the repeat. The resulting PCR products were size separated on
agarose gel and genotyped.
Of 27 samples with sufﬁcient high molecular weight DNA from blood,
the expansion size was analyzed by Southern blot hybridization. DNA
extracted from frontal cortex, temporal cortex and cerebellum of two long
and one short expansion carrier was also analyzed. In all, 20 μg genomic
DNA was digested with XbaI and separated on a 0.8% agarose gel. Capillary
blotting for at least 65 h was followed by ultraviolet crosslinking.
Membranes were hybridized with a non-repetitive digoxigenin-labeled
PCR probe overnight at 47 °C and subsequently washed in 0.1% sodium
dodecyl sulfate buffer containing decreasing concentrations of saline
sodium citrate. For probe detection, the procedure as described in the
digoxigenin application manual was used using CDPStar (Roche Applied
Science, Basel, Switzerland).
Autopsied brains of ﬁve patients with a C9orf72 repeat expansion were
stained with anti-ubiquitin antibody, AT8 against hyperphosphorylated
tau, 4G8 against β-amyloid, anti-FUS antibody and anti-TDP-43 antibody. In
addition, poly-(Gly-Ala) DPR proteins and p62 were stained on brain of
patient DR439.1 with a short repeat expansion and of two patients with a
long repeat expansion.
We developed two methylation sensitive restriction enzyme (MSRE)-
based assays followed by quantitative real-time PCR (MSRE-qPCR) to
quantify methylation levels of the G4C2 repeat and of an upstream ﬂanking
CpG island. The G4C2 MSRE-qPCR TaqMan assay with primers ﬂanking the
G4C2 repeat was based on the methylation sensitivity of HpaII evaluating
the CpG methylation state of each G4C2 unit and two CpGs in the 3'
ﬂanking region (Supplementary Figure S2). To analyze the 5' ﬂanking CpG
island, a HhaI-based MSRE-qPCR assay was developed using primers
upstream of the G4C2 repeat evaluating 1 of 17 CpGs (Supplementary
Figure S2). Digested and non-digested DNA samples were ampliﬁed using
the TaqMan Universal PCR Master Mix protocol on the ViiA7 Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA). In accordance with the
OneStep qMethyl kit of Zymo Research (Irvine, CA, USA), we calculated ΔCt
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values and the corresponding methylation percentages (100*2-ΔCt) to
estimate the methylation state of the studied amplicons. PCR ampliﬁcation
efﬁciencies were close to 100%. For the G4C2 assay, we selected individuals
homozygous for a normal short (S) (S/S: 2/2 and 5/5 units) or normal
intermediate (I) repeat length (I/I: 8/8 and ≥ 8/48 (up to 21) units). In total,
we analyzed the G4C2 repeat in blood genomic DNA of 42S/S and 12 I/I
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patients, 46S/S and 28 I/I controls (Supplementary Table 1). In addition,
only the wild-type allele of expansion carriers was studied because
expanded alleles are not ampliﬁable with repeat ﬂanking primers (42S and
18 I). Further, we included brain frontal cortex DNA of 11S/S patients,
3 I/I patients and 9S/S controls. We analyzed the 5' ﬂanking CpG island in
blood DNA of 80 repeat expansion carriers and frontal cortex, temporal
cortex and cerebellum of ﬁve expansion carriers, of whom one short
expansion carrier (DR439.1) and four with an expansion of480 units (long
expansion).
Bisulﬁte sequencing of the 5' ﬂanking CpG island was performed as
previously described14 on a representative selection of 26 DNA samples
from blood with a normal (S/S and I/I) or expanded (short and long)
repeat size.
We performed a reporter gene assay using constructs in which reporter
gene activity is driven by a C9orf72 promoter fragment. We selected a 2-kb
genomic C9orf72 promoter fragment (fragment 1) containing the G4C2
repeat and ﬂanking expression regulatory elements and a shorter 1.3-kb
genomic fragment (fragment 2) excluding the ﬁrst noncoding exons of
transcript variants 1 and 3 (Supplementary Figure S1). The DNA fragments
containing diverse repeat sizes were obtained by PCR ampliﬁcation of
genomic DNA of carriers of differently sized G4C2 alleles and were cloned
in a Gaussia luciferase reporter vector. In addition, we analyzed the effect
of two small deletions in the 3' sequence ﬂanking the G4C2 repeat: a
GTGGT deletion on a G4C2 allele with six units and a 5'-CGGGGCGG
GCCCGGGGGCGGGCC-3' deletion on a G4C2 allele with 12 units.
Reporter gene expression levels were assayed in human embryonic
kidney cells (HEK293T) and neuronal SH-SY5Y cells. Gaussia luciferase
activities were measured relative to Cypridina luciferase activities resulting
in relative luciferase activities.
Statistical analysis
As a result of small sample sizes and no normal distributions, we
performed a two-sided unpaired non-parametric Mann–Whitney U-test
without assuming equal variances to compare onset age and methylation
between short and long expansion carriers and the signiﬁcance of
differences in methylation state between different repeat sizes. Also
relative luciferase activities between constructs of different repeat lengths
were calculated by a two-sided Mann–Whitney U-test. For comparing
methylation state between two generations, we used a two-sided
Wilcoxon test.
The webappendix contains further technical details of the
procedures used.
RESULTS
Frequent occurrence of short C9orf72 G4C2 expansions
Although screening patients for the C9orf72 G4C2 repeat expan-
sion using the repeat-primed PCR assay, we observed in some
samples an atypical saw-tooth tail not extending beyond 500 bp
(60 units) as generally observed in G4C2 expansion carriers
(Figure 1a), which was suggestive for a shorter expansion. We
therefore designed an optimized short expansion PCR assay, and
analyzed blood DNA of 133 G4C2 expansion carriers. In most
expansion carriers, we observed only the wild-type allele,
indicating that their repeat expansion size was larger than 80
units, the approximate upper limit of the short expansion PCR
assay. However, we detected seven short expansion carriers
(7/133, 5.3%) of which six were affected by FTLD or ALS, including
four probands (4/72, 5.6%) (Figure 1b; Table 1). Fluorescent
fragment analysis showed a series of normally distributed peaks
with a 6-bp periodicity (Figure 1d) and a median size ranging
between 45 and 78 units (Table 1). We further conﬁrmed the
presence of a short expansion in blood DNA of all seven carriers
using Southern blot hybridization, and estimated their expansion
size between 55 and 100 repeat units (Figure 1c). The size
distribution of the expanded allele was within a narrow range in
all except one patient (DR439.5), showing additional bands of sizes
larger than 440 units (Figure 1c). In total, we assessed blood DNA
of 27 expansion carriers by Southern blot hybridization. The size of
the G4C2 expansion ranged from 55 units to over 2100 units, the
latter corresponding to the upper limit of size estimation with
acceptable accuracy using standard agarose gel electrophoresis.
The signals from blood DNA resulted in a smear or multiple bands
Figure 1. Sizing of C9orf72 repeat expansions. (a) Repeat-primed PCR results of one short repeat expansion carriers (DR439.1) and one patient
with a long expansion (DR454.1) showing the typical saw-tooth pattern. Short repeat expansions were recognized by a prematurely ending
tail, whereas the peaks of the long expansion extended far beyond 60 units. (b) Agarose gel showing short expansion PCR results of short
repeat expansion carriers and their relatives with a long repeat expansion (pedigrees in Figure 2), in blood DNA (left). PCR results on brain
DNA (right) are shown for three brain regions of one short and one long expansion carrier (fcx, frontal cortex; tcx, temporal cortex; cereb,
cerebellum). Strong lower bands represent the wild-type allele and weak upper bands the short expansion alleles. (c) Southern blot
hybridization results of blood DNA from seven short expansion carriers, two long expansion carriers and from two controls, and of brain DNA
from one short expansion carrier and two long expansion carriers. The wild-type allele is indicated with black dotted lines and the expansion
alleles with white dotted lines. Depending on the number of units on the wild-type allele, the detected fragment length of the non-expanded
allele varied between 2370 and 2466 bp. The speciﬁcity of the hybridization probe is demonstrated by the presence of two wild-type alleles
only in the controls. (d) Selected chromatograms resulting from short expansion PCR as shown in Figure 1b. The sample is indicated for each
chromatogram. The wild-type allele showed a discrete peak between 224 and 272 bp, whereas the expanded allele is represented by a range
of subsequent peaks with a Gaussian distribution between 446 and 794 bp.
Table 1. Clinical characteristics and size analyses of short G4C2 expansion carriers
Individual Family Phenotype AAO/current age (years) Disease duration (years) Family history Median repeat size SB
(min–max units)
Median repeat size PCR
(min–max units)
DR912.3 DR912 At risk 33 — F 55 (55–55) 45 (40–49)
DR911.1 DR911 FTLD 72 42 F 55 (55–55) 47 (44–54)
DR439.6 DR439 FTLD 69 45 F 55 (55–55) 50 (40–63)
DR439.1 DR439 FTLD 54 15 F 55 (55–55) 56 (47–76)
DR1044.1 DR1044 ALS 63 3 S 55 (55–55) 59 (52–78)
DR1045.1 DR1045 ALS 63 1 S 55 (55–55) 64 (57–82)
DR439.5 DR439 FTLD 52 411 F 75 (55–100) 78 (65–98)
And 4440
Abbreviations: AAO, age at onset; ALS, amyotrophic lateral sclerosis; F, familial; FTLD, frontotemporal lobar degeneration; S, sporadic; SB, Southern blot.
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(Figure 1c), making exact repeat expansion sizing unreliable.
Based on the 27 samples analyzed, a gap between short
expansions (up to 80 repeat units) and expansions of 4388
repeat units (long expansions) was apparent. Short expansion PCR
easily discriminated these two groups of short and long expansion
carriers.
Segregation analysis of short G4C2 expansions and association
with DPR pathology
Segregation analysis in the families of the four index patients
carrying a short repeat expansion in blood demonstrated
co-segregation with disease in family DR439 and DR911
(Figure 2). In family DR439, blood DNA of three sibs with FTLD
carried a short expansion of 50, 56 and 78 repeat units,
respectively (Figure 2, Table 1). As it was indicated above, one
of them (DR439.5) also had additional bands on Southern blot.
DR439.1 had a pre-symptomatic child DR439.12 aged 34 years
with a long expansion of 41100 repeat units (Figure 1c). Using
short tandem repeat markers ﬂanking C9orf72, we demonstrated
that the repeat expansion alleles segregated on the same disease
haplotype (Figure 2). Immunohistochemical analysis of autopsied
brain of patient DR439.1 carrying a short expansion of 56 repeat
units in blood, showed TDP-43-positive neuronal cytoplasmic
inclusions in the hippocampus and frontal cortex compatible with
TDP-43 type B proteinopathy.51 Dot-like neuronal cytoplasmic
inclusion in the frontal lobe (premotor cortex), hippocampal
dentate gyrus and the granular cell layer of the cerebellum were
observed after p62 and poly-GA DPR immunostaining (Figure 3
and Supplementary Figure S3). Other aggregating DPR proteins
(poly-GP, poly-GR, poly-AP and poly-PR) had been observed in the
frontal cortex of this patient.22,24 Short expansion PCR of DNA
extracted from the frontal and temporal cortex of patient DR439.1
were consistent with the short expansion size determined in
blood DNA, however, the weak signal on Southern blot of the
short expansion allele and additional signals corresponding to
larger expansion sizes indicated mosaicism in these brain areas
(Figure 1). The signal of the short expansion was weakest or even
absent in cerebellum in favor of a relatively strong signal
corresponding to an expansion of 41100 repeat units on
Southern blot hybridization (Figure 1). Two other patients with a
long expansion in blood DNA did not show a short expanded
allele in brain (Figure 1). We compared the DPR/p62 and TDP-43
pathology of DR439.1 with the pathology of two patients with a
Figure 2. Segregation of short repeat expansions and possible anticipation in G4C2 expansion families. Three families are shown in which a
short repeat expansion was detected (DR439, DR911 and DR912). Filled symbols are indicating patients with below their respective age at
onset (AAO) in years (y). Age at death (AAD) is shown for individuals who died at old age without symptoms. Individuals with DNA are
depicted with an asterisk right of the symbol. The C9orf72 repeat length is included in the haplotype indicated in number of units (u). The
numbers in diamonds indicate the number of unaffected at-risk individuals. The disease haplotype is shown with light green bars. In families
DR439 and DR911, a short repeat expansion segregates with disease on a speciﬁc disease haplotype. Clinical characteristics of presented
individuals can be found in Table 1 and Supplementary Table 2. Four parent–offspring pairs (DR439, DR454, DR659 and DR598) presented with
evidence for anticipation, including methylation (delta Ct) increase (DR439, DR659 and DR598), age at onset decrease (DR454, DR659 and
DR598) and/or repeat size increase (DR439) across two generations.
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long expansion.2 Visual inspection and semiquantitative analysis
of DPR/p62 and TDP-43 inclusion load in frontal cortex,
cerebellum and hippocampus did not show striking differences
between the carrier of a short expansion in blood with some
indication of mosaicism in brain and long expansion carriers
(Figure 3 and Supplementary Figure S3).
In family DR911, the index patient (DR911.1) presented with
late-onset FTLD (72 years), while the three affected sibs were
diagnosed with ALS and onset ages 69, 67 and 58 years (Figure 2,
Table 1). The parents died at age 67 and 74 years without
documented dementia or ALS symptoms. We obtained DNA of the
index patient and of one affected sib (DR911.6) and showed the
presence of a short expansion of 47 units and a long expansion of
480 units, respectively (Figure 2). One of the asymptomatic at-risk
individuals in the youngest generation carried a repeat expansion
of480 units. Repeat expansions in the other unaffected children
were excluded. Haplotype analysis conﬁrmed that the expansions
segregated on the same disease haplotype (Figure 2).
In family DR912, there were two affected sibs with early-onset
FTLD (DR912.1, 45 years and DR912.6, 49 years). One of the
parents died from ALS at age 66 years after 1 year of disease
(Figure 2). We obtained DNA of the two affected sibs (DR912.1 and
DR912.6) and four at-risk relatives, all carrying a repeat expansion.
Only the asymptomatic carrier DR912.3 showed a short expansion
of 45 units, and the short and the long expansions were located
on the same haplotype (Figure 2).
Onset age and DNA methylation are associated with G4C2
expansion size
When we compared onset age differences between 6 patients
with a short expansion and 51 patients with a long expansion of
Figure 3. DPR pathology of a patient with a short expansion compared with a patient with a long expansion. Immunohistochemistry with
poly-GA-speciﬁc antibodies detects DPR-positive dot-like neuronal cytoplasmic inclusions in Brodmann area 6 of the frontal cortex (a-b), the
granular cell layer of the cerebellum (c-d) and the dentate gyrus of the hippocampus (e-f) of a patient with a short repeat expansion (56 units)
(a–c–e), comparable with the inclusions in a patient with a long repeat expansion (480 units) (b–d–f). Scale bars denote 10 μm.
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whom the age at onset was recorded (mean 53.1 years, range
29-70 years), we calculated a signiﬁcantly later onset age in the
short expansion carriers (mean 62.2 years, range 52–72 years;
P= 0.037; Figure 4a). Notably, the patient DR439.5 carrying a pool
of short and long expansion sizes had the earliest onset age
(52 years).
As suggested in previous DNA methylation studies of G4C2
expansion carriers,11–15 the qPCR assay in the 5' ﬂanking CpG
island revealed a signiﬁcant increase of methylation in blood DNA
(Po0.0001) and brain DNA (P= 0.0044) of patients carrying an
expansion compared with patients without expansion, normalized
for the repeat size on their normal allele(s) (Figure 4d).
Further, we examined whether the observed differences in
onset age between short and long expansion carriers could be
explained by altered DNA methylation of the 5' ﬂanking CpG
island. Indeed, the methylation levels in the 5' ﬂanking CpG island
(Supplementary Figure S2) were signiﬁcantly lower in short
expansion carriers in blood DNA (Po0.0001) and brain DNA
(P= 0.031; Figure 4b). Patient DR439.5, carrying a pool of short and
long expansion sizes in blood, showed the highest methylation
level in blood DNA. Three different brain regions of patient
DR439.1 showing a pool of short and long expansion sizes were
examined (frontal cortex, temporal cortex and cerebellum), of
which the cerebellar region showed the highest methylation
consistent with untraceable quantity of short expansion sizes in
this brain region (Figure 1c).
Parent–offspring pairs show disease anticipation
As exact expansion sizes were lacking in most of the parent–
offspring pairs and because the young age of most of the
asymptomatic expansion carriers in the youngest generation, no
robust conclusions regarding repeat ampliﬁcation and disease
anticipation could be drawn based on onset ages or expansion
sizes only. In one parent–offspring pair (DR439.1 and DR439.12),
an increase in expansion size with about 1000 units was observed,
although the offspring, aged 34 years, was not yet affected
(Figures 1 and 2; Table 1; Supplementary Table 2). Three other
affected parent–offspring pairs in families DR454, DR659 and
DR598 with DNA available (Figure 2), showed a 16, 25 and 19 years
earlier onset age, respectively, in the affected child compared
with the parent (Figure 2, Supplementary Table 2). In each of
Figure 4. Association of G4C2 size with disease onset age and DNA methylation of the G4C2 repeat and the 5' ﬂanking CpG island.
(a) Comparison of age at onset (AAO) between patients with a short expansion (o80 units) and patients with a long expansion (480 units).
(b) Comparison of the methylation level of the 5' ﬂanking CpG island between patients with a short expansion (o80 units) and patients with
a long expansion (480 units) in DNA from blood and brain. Brain regions include frontal cortex, temporal cortex and cerebellum.
(c) Methylation differences of the 5' ﬂanking CpG island in 15 parent–offspring pairs of 11 families. Methylation levels are shown in red for the
parents and in green for the offspring. Clinical characteristics of presented individuals can be found in Supplementary Table 2. (d) HhaI
MSRE-qPCR results of the 5' ﬂanking CpG island are presented for expansion carriers (S/exp and I/exp) versus patients without expansion with
short/short (S/S) and intermediate/intermediate (I/I) genotype stratiﬁed for normal short (S) or intermediate (I) repeat length of the normal
alleles (a), and for controls with S/S and I/I genotype (a). (e) HpaII MSRE-qPCR results of the G4C2 repeat are shown for patients and controls
with S/S and I/I genotype and for expansion carriers with a normal short or intermediate wild-type allele. Disease status and genotype are
indicated on the X axis, whereas the Y axis shows the methylation ratio (in %) for each sample. The mean is represented by black horizontal
bars for each subcategory of samples. The signiﬁcance of differences in methylation was calculated using the Mann–Whitney U-test. P-values
are presented above the bars (****Po0.0001; **Po0.01; *Po0.05).
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these pairs, short expansion PCR excluded a short expansion
(480 units).
As a result of the correlation between expansion size, onset age
and methylation, we analyzed methylation differences across
generations in 15 parent–offspring pairs of 11 families
(Supplementary Table 2). A methylation increase up to 35.6%
was apparent in 13 pairs including DR439, DR454, DR659 and
DR598 (P= 0.0034) (Figure 4c; Supplementary Table 2), supporting
an intergenerational repeat ampliﬁcation as shown in DR439 and
possibly resulting in an earlier onset age as shown in DR454,
DR659 and DR598.
Epigenetic analysis of the C9orf72 promoter in intermediate repeat
carriers
We previously suggested that intermediate repeats (7–24 units)
might act as risk alleles predisposing the carriers to G4C2
expansions.25 In a follow-up study, we observed in a group of
ALS and FTLD–ALS patients (N= 135) that homozygous carriers of
intermediate repeat alleles showed a signiﬁcantly increased risk
(P= 0.038; 95% conﬁdence interval = 2.075 (1.041–4.137)). There-
fore, we compared the 5' CpG island methylation of homozygous
normal intermediate repeat carriers (I/I) (7–24 units) with
homozygous normal short repeat carriers (S/S) (2–6 units) and
demonstrated a slight but signiﬁcantly higher methylation in
I/I carriers in controls (Po0.0001) but not in patients (P= 0.1471;
Figure 4d).
In addition, we compared methylation states of normal short
and intermediate G4C2 repeats itself using a G4C2 MSRE-qPCR
assay. We showed a slight but signiﬁcant increase in methylation
level of the G4C2 repeat in blood DNA from I/I carriers compared
with S/S carriers, in the patient (P= 0.005) and control groups
(Po0.0001; Figure 4e). Also intermediate wild-type alleles of
expansion carriers are signiﬁcantly more methylated than normal
short wild-type alleles (Po0.0001; Figure 4e).
Notably, the degree of methylation is very low (o5%) in the
groups of individuals without long expansions versus ~ 10% in
expansion carriers. Sequencing of bisulﬁte-treated DNA samples
detected 5' CpG methylation in long expansion carriers with at
least 5% methylation and no 5' CpG methylation in short
expansion carriers or normal repeat carriers (Supplementary
Figure S4).
Increased DNA methylation in patients with a normal repeat
compared with control persons with a normal repeat was
apparent in both MSRE-qPCR assays in blood (P= 0.0133 for the
5' CpG island and P= 0.0004 for the G4C2 repeat). Also, 5' CpG and
G4C2 methylation was signiﬁcantly higher in brain than in blood of
expansion carriers (Figure 4b) and patients with a normal repeat
(Po0.0001; Figures 4d and 4e).
Variability in repeat sizes and ﬂanking sequences is associated
with decreased C9orf72 transcriptional activity
We further investigated whether the G4C2 repeat size has a direct
effect on the transcriptional activity of the C9orf72 promoter. In
addition, as we observed a signiﬁcantly higher amount of indels in
the 3' ﬂanking sequence in patients without C9orf72 expansion
(7/379 = 1.85%) than in controls (4/752 = 0.53%; P= 0.033; N= 379),
we also evaluated the effect of these indels on transcriptional
activity.
In HEK293T cells, we observed a highly signiﬁcant decrease of
transcriptional activity of promoter fragment 1, containing G4C2
repeat alleles with intermediate length within the normal range (9,
14, 19 and 24 units) or within the size range of unclear
pathogenicity (31 and 38 units), compared with the normal
reference allele with two repeat units (Po0.0001; Figure 5a). The
promoter activity of the 24 units fragment gradually dropped to
57%, which is signiﬁcantly lower than the 19 units fragment
(P= 0.010). However, the promoter activity of the fragments with
31 and 38 repeat units was not signiﬁcantly changing (Figure 5a),
possibly due to repeat instability (Supplementary Figure S5). For
fragment 2, the same trend was observed, although the most
signiﬁcant drop in transcriptional activity was observed for the
fragment with 14 repeat units compared with the fragments with
2 and 9 units (Po0.0001; Figure 5c). For both fragments 1 and 2,
the presence of the 5-bp deletion (6U-del) or the 23-bp deletion
(12U-del), resulted in a drastic decrease in transcriptional activity
compared with the reference fragment with 6 units (P= 0.0002 for
fragment 1; P= 0.0034 for fragment 2) or 12 units (Po0.0001 for
fragment 1; P= 0.0004 for fragment 2) (Figures 5b and d).
Similarly, in SH-SY5Y cells the transcriptional activity of the
promoter fragment 1 was signiﬁcantly decreased for all repeat
sizes compared with the normal reference repeat of two units
(Po0.0001) with a maximal drop to 53% for the 38 units fragment
(Figure 5e). Again, the 6U-del and the 12U-del in the 3' ﬂanking
sequence resulted in a signiﬁcant transcriptional decrease
compared with the respective reference fragment with 6 repeat
units (P= 0.0002) or 12 repeat units (Po0.0001; Figure 5f).
DISCUSSION
The basis for clinical heterogeneity and suggestive anticipation
among C9orf72 patients is not well understood. The effect of the
repeat size on the clinical characteristics of repeat expansion
disorders is well known. In our study, G4C2 expansion sizes in
blood varied considerably between and within families (45 to
42100 units), which is largely comparable with previous
reports1,6,26–32 and indicate a high degree of instability of the
expanded repeat. We identiﬁed 5.3% carriers of a short expansion
with a repeat size between 45 and 78 units in blood. We were able
to amplify the expanded allele, and the short expansions could
also be visualized by Southern blot hybridization without other
larger bands in six of seven patients (Figure 1c). In two families,
DR439 and DR911, we provided evidence that G4C2 expansion
carriers with a repeat as short as 47 repeat units in blood can
present with FTLD or ALS (Table 1; Figure 2). For instance, patient
DR439.1 showed numerous p62/DPR-positive neuronal cytoplas-
mic inclusion in different affected brain regions, a characteristic
pathological hallmark of C9orf72 patients22–24 without remarkable
differences compared with long expansion carriers. However, the
short expansion in this subject was only partially apparent in the
frontal and temporal cortex and absent in cerebellum. Several
studies reported instability of the repeat from 16 units on due to
somatic mosaicism across different tissues,26,30,38 which compli-
cates determination of the repeat pathogenicity based on repeat
sizing in blood-derived DNA. However, intra-individual variation of
repeat number between tissues was higher than the variation
within each tissue group.38 Although other studies reported short
expansions of o100 units,6,27,38,52 this is the ﬁrst report
demonstrating co-segregation of FTLD and ALS with an expansion
outside the pathogenic size range from 400 to 4400 repeat
units.26,30 A short C9orf72 repeat expansion of 66 units causes
TDP-43 pathology, neuronal loss and behavioral deﬁcits in a
recent mouse model, corroborating our ﬁndings.53 Although
expansions of any size can be recognized by the repeat-primed
PCR assay, the detection of expansions as short as 47 units
underscores the importance of the short expansion PCR assay as a
fast and reliable screening method for identifying expansions up
to about 80 repeat units.26
Expansion carriers without a detectable expanded allele on
short expansion PCR were classiﬁed as 'long expansions' (480
units), as exact sizing of expansions in the higher size rang was
inappropriate because of the smeared signals because of
mosaicism and the limited resolution of an agarose gel above
15 kb. In contrast to other studies,1,6,15,26–30,32,38 we were able to
provide a signiﬁcant later age of disease onset in patients with a
short expansion than those with a long expansion (Figure 4a). To
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reach this result, we used only blood and brain-derived DNA and
no DNA of cell lines. In addition, a standardized clinical diagnostic
protocol ensured a consistent onset age estimate in all patients.
Further, we showed that this difference in age at onset might be
explained by lower methylation of the CpG island upstream of
G4C2 in patients with short expansion sizes in blood, as well as in
brain (Figure 4b). Others also found hypermethylation of the CpG
island in expansion carriers11–15 but a positive association with
expansion size was never reported. Only one study found a
marginally signiﬁcant association of hypermethylation with
shorter repeat size in blood only.15 Further investigation and
replication studies of age at onset and methylation correlations
with repeat size in large cohorts are needed.
We gathered evidence that anticipation might have a role in
C9orf72 families segregating a G4C2 expansion by comparing
onset ages, expansion sizes and methylation states across
generations of parent–offspring pairs. First, a parent–offspring
pair of family DR439 showed an increment of about 1000 repeat
Figure 5. C9orf72 reporter gene analyses in HEK293T and SH-SY5Y cells. Bars represent relative Gaussia/Cypridina luciferase activities (RLA) for
each of the C9orf72 constructs containing different G4C2 repeat lengths in fragment 1 (a-e) or fragment 2 (c) or different deletions in the 3'
ﬂanking sequence in fragment 1 (b-f) and fragment 2 (d), as indicated in the X axis. Values and error bars represent the mean± S.E.M. relative
to the wild-type reference allele of two units (Y axis). The signiﬁcance of differences in expression was calculated using the Mann–Whitney
U-test. P-values are presented above the bars (****Po0.0001; ***Po0.001; **Po0.01; *Po0.05). Signiﬁcant P-values are only indicated with
the ﬁrst subsequent allele that is signiﬁcantly different.
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units and a methylation increase from the affected parent to
the asymptomatic child (Figure 2, Supplementary Table 2).
Remarkably is that the parents of the four affected sibs died at
75 and 86 years without documented dementia or ALS symptoms,
potentially suggesting that they did not carry a repeat expansion.
The data obtained in family DR439 suggest genetic anticipation
over three generations. Other modifying factors may also
inﬂuence the clinical phenotype in this family since the index
patient had a later onset age (69 years) than his two affected sibs
(52 and 54 years). This is in line with previously reported data of an
identical twin discordant for ALS but showing the same repeat
expansion size and methylation level.54 Second, three affected
parent–offspring pairs in three families (DR454, DR659 and DR598)
showed a 16, 25 and 19 years earlier onset age, respectively and a
higher methylation state of the ﬂanking CpG island in the child
compared with the affected parent (Figure 2). In 9 of 11 other
parent–offspring pairs without repeat sizing or onset age data, a
methylation increase was apparent from parent to offspring
(Supplementary Table 2).
Several reports described an earlier onset age in each younger
generation suggesting disease anticipation, however, not all
C9orf72 families showed a decrease in onset age across
generations.2,41–46 Also, the anticipation data obtained in the
families was largely not validated by attempts to size the repeat
expansion. In our study, we could also not correlate an earlier
onset age with an increase in repeat size in each parent–child pair,
for example, in families DR454 and DR659, because of the
technical limitations of the current methods used for sizing the
C9orf72 repeat expansions. Nonetheless, our data are highly
supportive of genetic anticipation in C9orf72 families for several
reasons. We analyzed onset age data in individual affected
parent–child pairs instead of between onset age data that was
pooled per generation. Also, we made optimal use of the
detection of short C9orf72 repeat expansions that were segregat-
ing in families, to directly observe in individual generations the
ampliﬁcation of the C9orf72 repeat. Further, we showed associa-
tion between expansion size, onset age and methylation state
(see above). The observation of the repeat size contraction as
observed in one parent–child pair of family DR912 (DR912-3;
Figures 2 and 4c), and possibly other modifying factors, may
explain the occurrences of onset age decrease and methylation
increase (Figure 4c; Russ et al.15) in some families.
Genetic anticipation because of repeat instability, together with
the incomplete penetrance and wide range of onset age of
disease in C9orf72 carriers,41 has important consequences for
genetic counseling of relatives of a C9orf72 carrier. Likely one of
the two unaffected parents carries a repeat expansion, potentially
a shorter one, in the absence or the presence of undetected mild
symptoms hampering reasonable predictions of risk of relatives as
well as of onset of the disease symptoms or clinical phenotype in
carriers.55,56
The emergence of two clinically and pathologically distinct
diseases,57 FTD and ALS, in the C9orf72 carriers is remarkable and
might potentially be explained by modifying factors. It is possible
that differences in repeat expansion sizes or in the presence of
interruptions in the C9orf72 repeat sequence might inﬂuence the
clinical manifestation. To date, this hypothesis cannot be
adequately tested as there is no method available that allows to
determine the precise size or repeat content of the expansion. The
current methods, repeat-based PCR ampliﬁcation or Southern
blotting, provide at the best an approximate size measure of the
expansion without information on the purity of the repeat
sequence. Another possibility is that differences in the degree or
pattern of methylation of the C9orf72 promoter region can explain
the clinical divergence. In our study, we did not observe
differences between FTLD and ALS expansion carriers in blood
(Supplementary Figure S6). However, methylation differences in
other CpG islands, including the G4C2 repeat itself, or in other
tissues than blood cannot be excluded. Further, it is possible that
genetic variation in other genes may drive the disease pathology
toward a speciﬁc side of the clinical FTD/ALS continuum. Genetic
modiﬁers for clinical expression of FTLD have already been
reported, including TMEM106B, which exerted a protective effect
for FTLD in C9orf72 carriers,58 and ATXN2, which increased risk of
C9orf72 carriers for ALS.59,60 Also, the co-occurrence of mutations
in multiple FTD and ALS genes might modify the disease
phenotype (reviewed in Lattante et al.61). A hypothesis-free
approach to ﬁnd genetic modiﬁers of the FTLD–ALS continuum
could be the use of single-nucleotide polymorphism data
obtained in genome-wide association studies comprising FTLD
and ALS patients,62 or the exploration of genome or exome data
generated in large patient cohorts.63
Further, we observed slight but signiﬁcant G4C2 repeat
methylation differences in intermediate (I) G4C2 risk allele carriers
versus normal short (S) repeat carriers in blood (Figure 4).
Although the methylation percentages of normal repeat carriers
were in a very low range and not detected in previous reports
using qualitative methods,13,14 signiﬁcant differences were
calculated in both independent quantitative assays measuring
methylation of the 5' CpG island and of the G4C2 repeat itself,
supporting the correctness of the data. Notably, the higher
methylation levels in I/I versus S/S carriers were mostly derived
from the homozygous intermediate carriers with at least one allele
of 48 units. As these longer intermediate repeat alleles are
relatively under-represented in the small I/I patient group
(Supplementary Table 1), the methylation of the ﬂanking CpG
island was not signiﬁcantly different between S/S and I/I patient
groups. Methylation of pathological G4C2 expansions could not be
studied by our method as PCR ampliﬁcation is technically difﬁcult.
Nevertheless, the correlation between the methylation state of the
G4C2 repeat and that of the 5' ﬂanking region in normal repeat
carriers suggested that hypermethylation of the G4C2 repeat could
also have a role in carriers of G4C2 expansions. This assumption
was recently shown by a qualitative assay.10 Although a later age
at inclusion was previously associated with longer repeat sizes15,30
and DNA methylation levels might change with aging,64 in this
study, differences in age at inclusion could not explain the
observed correlations in S/S, I/I and expansion carriers
(Supplementary Figure S6). Of interest, DNA methylation was
higher in patients than in controls in blood and brain suggesting a
risk-increasing effect of methylation caused by other factors than
repeat length. Also of note, C9orf72 methylation was remarkably
higher in brain than in blood. Despite these tissue-speciﬁc
methylation levels, the repeat size effect on methylation was also
observed in brain, as methylation in blood and brain are positively
correlated, as previously described.15
To evaluate the effect of the hypermethylated intermediate
repeat sizes on C9orf72 promoter activity, we developed an in vitro
reporter gene assay. As our preliminary results already
suggested,25 here we established a highly signiﬁcant gradual
decrease of C9orf72 promoter activity with an increasing number
of G4C2 repeat units in human kidney and neuroblastoma cell lines
(Figure 5), the latter most closely related to the affected neurons in
patients. Our promoter study showed that increased methylation
of CpG sequences in larger repeats and hence transcriptional
silencing of the promoter is most likely one of the mechanisms of
how an increasing repeat length can lead to decreased promoter
activity, but other possibilities might also have a role. First, an
excess of transcription factor binding sites in the lengthened G4C2
motif and the tight complex formation of G-quadruplexes65 might
hamper proper transcription. Second, the DNA loop formed
between a potential distant promoter element and the C9orf72
promoter complex might become too large to correctly connect
both components.
Further, the transcriptional decreasing effect of intermediate
repeat lengths and small deletions in the 3' ﬂanking sequence
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could probably explain the observed nominally signiﬁcant
association of intermediate repeat alleles and indels in the
3' ﬂanking sequence with increased disease risk in the Belgian
ALS and FTLD–ALS population, possibly through subtle changes in
C9orf72 expression. The 23- bp deletion in the 3' ﬂanking
sequence has a more drastic effect on decreased promoter
activity than the GTGGT deletion. The GTGGT deletion joins the
G4C2 repeat with the 3' ﬂanking sequence thereby creating an
imperfect G4C2 repeat with 6 units more, mimicking the effect of
an intermediate 12 units repeat. Alternatively, both deletions
could result in deﬁciency of essential core promoter elements.
Altogether, our data are in favor of a loss-of-function hypoth-
esis. Indeed, epigenetic changes including the observed DNA
hypermethylation by this and other studiesx11–15 and histone
trimethylation9 could explain the decreased C9orf72 brain
expression in repeat expansion carriers1,2,6–9 through transcrip-
tional silencing, as seen in other repeat expansion disorders, for
example, Fragile X syndrome.16,17,66 An association between
hypermethylation of a CpG island ﬂanking an expanded repeat
and repeat expansion size has also been found in the ﬁrst intron of
the Friedreich ataxia syndrome gene FXN, which could possibly be
correlated with reduced mRNA levels.18,67 Accordingly, expression
of C9orf72 transcripts 2 and 3 was lower in frontal and temporal
cortex of two long expansion carriers, than the C9orf72 expression
of the short expansion carrier DR439.1, the latter located within
the large expression range of control individuals without
expansion (Supplementary Figure S7). In favor of this loss-of-
function hypothesis are two C9orf72 models: a zebraﬁsh knock-
down model showing axonal degeneration of motor neurons7
and a C. elegans knock-out model displaying age-dependent
paralysis and neurodegeneration of GABAergic motor neurons.68
Alternatively, the later onset age in short repeat expansion carriers
might also be in favor of an RNA toxicity or DPR protein toxicity
mechanism as unstably growing repeat lengths will result in a
gradually more harmful effect, as seen in other repeat expansion
diseases, for example, myotonic dystrophy type I.39 This hypoth-
esis is supported by studies identifying sense and antisense RNA
foci and DPR protein aggregates formed by the expanded C9orf72
G4C2 repeat in human neurons of different tissues involved in
FTLD and ALS in vivo1,20–24 and RNA foci in induced pluripotent
stem cell–derived human neurons,69,70 and by the sequestration
of RNA-binding proteins in the pathological deposits of repeat
expansion carriers.19,21,71 The disease causing role of DPR protein
deposits was shown in a Drosophila model72 and DPR neurotoxi-
city was observed in primary neurons.73 Moreover, RNA foci
burden in the frontal cortex showed a signiﬁcant inverse
correlation with onset age74 and repeat length72 corroborating
our ﬁndings. Some observations might have benign side effects
but, more likely, different mechanisms together are involved in
the disease process. Alternatively, hypermethylation might be a
rescue mechanism to prevent the formation of RNA foci12 and
might therefore be neuroprotective.15,75
This study is meaningful in assessing disease risk and severity
and to provide better diagnostic guidelines for genetic testing and
counseling. Our data indicate that methylation might serve as a
potential biomarker. Aberrant DNA methylation is becoming a
promising therapeutic target in FTLD and ALS because abnormal
DNA methylation might be involved in FTLD76 and ALS.77,78 If RNA
toxicity also has a role in the disease process, the use of antisense
oligonucleotides targeting and decreasing RNA foci will be
promising as a potential therapeutic approach.70,79,80
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